Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide
In patients with mCRPC, the I/N PSA is a promising predictive and prognostic biomarker for first-line ENZ treatment and may provide personalized approaches in daily practice.
Authors
- Sohei Yamamura
- Takuo Matsukawa (ORCID: https://orcid.org/0009-0009-4418-399X)
- Naohiro Fujimoto (ORCID: https://orcid.org/0000-0002-5256-6415)
- Masahiro Matsumoto (ORCID: https://orcid.org/0000-0001-8374-3595)
- Eiji Kashiwagi (ORCID: https://orcid.org/0000-0001-9424-3764)
- Yui Mizushima
- Ikko Tomisaki (ORCID: https://orcid.org/0000-0002-7818-0780)
- Akinori Minato (ORCID: https://orcid.org/0000-0001-6303-1128)
- Yujiro Nagata
- TOMEI SUGI
- Yoshihiro Sugita
- K. Jojima
- T Takaba
- Katsuyoshi Higashijima
Institutions
- University of Occupational and Environmental Health Japan (JP)
- Kurosawa Hospital (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/invivo.14016
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52